1
Clinical Trials associated with Dual-targeting CLDN18.2 and PD-L1 CAR-T cells(Sichuan University)A Phase I, Open-label, Single-arm, Dose-escalation and Expansion Study of Specific Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors
Claudin18.2(CLDN18.2) is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in many solid tumors, especially in gastric cancer and pancreatic cancer. The CLDN18.2/PD-L1 dual-targeting CAR-T will be investigated in patients with CLDN18.2-positive advance solid tumors.
100 Clinical Results associated with Dual-targeting CLDN18.2 and PD-L1 CAR-T cells(Sichuan University)
100 Translational Medicine associated with Dual-targeting CLDN18.2 and PD-L1 CAR-T cells(Sichuan University)
100 Patents (Medical) associated with Dual-targeting CLDN18.2 and PD-L1 CAR-T cells(Sichuan University)
100 Deals associated with Dual-targeting CLDN18.2 and PD-L1 CAR-T cells(Sichuan University)